Abstract
Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
Keywords: filoviral particles, furin-like endoprotease, ICAM, TNF-related apoptosis-inducing ligand (TRAIL), coagulation defects, proinflammatory
Current Molecular Medicine
Title: Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures
Volume: 5 Issue: 8
Author(s): Lisa E. Hensley, Steven M. Jones, Heinz Feldmann, Peter B. Jahrling and Thomas W. Geisbert
Affiliation:
Keywords: filoviral particles, furin-like endoprotease, ICAM, TNF-related apoptosis-inducing ligand (TRAIL), coagulation defects, proinflammatory
Abstract: Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
Export Options
About this article
Cite this article as:
Hensley E. Lisa, Jones M. Steven, Feldmann Heinz, Jahrling B. Peter and Geisbert W. Thomas, Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures, Current Molecular Medicine 2005; 5 (8) . https://dx.doi.org/10.2174/156652405774962344
DOI https://dx.doi.org/10.2174/156652405774962344 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Potential of Thiazole Derivatives: A Retrospective Review
Mini-Reviews in Medicinal Chemistry Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Preparation and Evaluation of Chitosan Submicroparticles Containing Pilocarpine for Glaucoma Therapy
Current Drug Delivery Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Phospholipase A2 Inhibitors as Potential Anti-Inflammatory Agents
Current Pharmaceutical Design Synthesis and Characterization of Water-soluble Conjugates of Cabazitaxel Hemiesters-Dextran
Anti-Cancer Agents in Medicinal Chemistry Comparative Bioavailability of Two Oral Formulations of Clozapine in Steady State Administered in Schizophrenic Volunteers Under Individualized Dose Regime
Current Clinical Pharmacology Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design